327 related articles for article (PubMed ID: 30666105)
1. Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S.
Pan J; Shao X; Zhu Y; Dong B; Wang Y; Kang X; Chen N; Chen Z; Liu S; Xue W
Int J Nanomedicine; 2019; 14():431-440. PubMed ID: 30666105
[TBL] [Abstract][Full Text] [Related]
2. Surface-enhanced Raman spectroscopy of preoperative serum samples predicts Gleason grade group upgrade in biopsy Gleason grade group 1 prostate cancer.
Qian H; Shao X; Zhu Y; Fan L; Zhang H; Dong B; Wang Y; Xu F; Zhen W; Kang X; Chen N; Liu S; Pan J; Xue W
Urol Oncol; 2020 Jun; 38(6):601.e1-601.e9. PubMed ID: 32241690
[TBL] [Abstract][Full Text] [Related]
3. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
4. Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy.
Qian H; Wang Y; Ma Z; Qian L; Shao X; Jin D; Cao M; Liu S; Chen H; Pan J; Xue W
Int J Nanomedicine; 2022; 17():1635-1646. PubMed ID: 35411143
[TBL] [Abstract][Full Text] [Related]
5. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
[TBL] [Abstract][Full Text] [Related]
6. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
[TBL] [Abstract][Full Text] [Related]
8. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
[TBL] [Abstract][Full Text] [Related]
9. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
10. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
Merriman KM; Harmon SA; Belue MJ; Yilmaz EC; Blake Z; Lay NS; Phelps TE; Merino MJ; Parnes HL; Law YM; Gurram S; Wood BJ; Choyke PL; Pinto PA; Turkbey B
AJR Am J Roentgenol; 2023 Dec; 221(6):773-787. PubMed ID: 37404084
[No Abstract] [Full Text] [Related]
11. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
[TBL] [Abstract][Full Text] [Related]
12. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
[TBL] [Abstract][Full Text] [Related]
13. Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models.
Boehm K; Larcher A; Beyer B; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Heinzer H; Graefen M; Budäus L
Eur Urol; 2016 Jun; 69(6):1038-43. PubMed ID: 26272236
[TBL] [Abstract][Full Text] [Related]
14. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients.
Yoshida T; Nakayama M; Takeda K; Arai Y; Kakimoto K; Nishimura K
Urol Int; 2012; 89(1):45-51. PubMed ID: 22441013
[TBL] [Abstract][Full Text] [Related]
15. Postoperative early ultrasensitive prostate-specific antigen identifies patients at risk for biochemical recurrence in margin positive prostate cancers: a single-center study.
Hatano K; Okusa T; Ishizuya Y; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Jpn J Clin Oncol; 2017 Jan; 47(1):74-79. PubMed ID: 27733509
[TBL] [Abstract][Full Text] [Related]
16. [Is CAPRA-S score a valid tool in our environment to predict biochemical recurrence, metastasis and death after radical prostatectomy?].
Bengió RG; Arribillaga L; Bengió V; Montedoro A; García Önto H; Epelde J; Cordero E; Oulton G; Bengió RH
Arch Esp Urol; 2016 Nov; 69(9):621-626. PubMed ID: 27845693
[TBL] [Abstract][Full Text] [Related]
17. Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy.
Seo WI; Kang PM; Kang DI; Yoon JH; Kim W; Chung JI
J Korean Med Sci; 2014 Sep; 29(9):1212-6. PubMed ID: 25246738
[TBL] [Abstract][Full Text] [Related]
18. A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
Athanasiou A; Tennstedt P; Wittig A; Huber R; Straub O; Schiess R; Steuber T
PLoS One; 2021; 16(11):e0259093. PubMed ID: 34767586
[TBL] [Abstract][Full Text] [Related]
19. Surface-enhanced Raman spectroscopy of blood serum based on gold nanoparticles for the diagnosis of the oral squamous cell carcinoma.
Tan Y; Yan B; Xue L; Li Y; Luo X; Ji P
Lipids Health Dis; 2017 Apr; 16(1):73. PubMed ID: 28388900
[TBL] [Abstract][Full Text] [Related]
20. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
Zhao KH; Hernandez DJ; Han M; Humphreys EB; Mangold LA; Partin AW
Urology; 2008 Aug; 72(2):396-400. PubMed ID: 18372031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
